Similar articles

• Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

  Annemans L, Rémy V, Oyee J, Largeron N. Annemans L, et al. Pharmacoeconomics. 2009;27(3):231-45. doi: 10.2165/00019053-200927030-00006. Pharmacoeconomics. 2009. PMID: 19354343
• Cost-effectiveness and value-based prices of the 9-valent human papillomavirus vaccine for the prevention of cervical cancer in China: an economic modelling analysis.

  Jiang Y, Ni W, Wu J. Jiang Y, et al. BMJ Open. 2019 Nov 24;9(11):e031186. doi: 10.1136/bmjopen-2019-031186. BMJ Open. 2019. PMID: 31767588 Free PMC article.
• Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.

  Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G. Demarteau N, et al. Value Health. 2012 Jul-Aug;15(5):622-31. doi: 10.1016/j.jval.2012.02.012. Epub 2012 Jun 12. Value Health. 2012. PMID: 22867770
• [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].

  Westra TA, Daemen T, Postma MJ, Wilschut JC. Westra TA, et al. Ned Tijdschr Geneeskd. 2009;153:A356. Ned Tijdschr Geneeskd. 2009. PMID: 19930733 Review. Dutch.
• The quadrivalent human papillomavirus vaccine: potential factors in effectiveness.

  Zonfrillo NJ, Hackley B. Zonfrillo NJ, et al. J Midwifery Womens Health. 2008 May-Jun;53(3):188-194. doi: 10.1016/j.jmwh.2007.12.015. J Midwifery Womens Health. 2008. PMID: 18455092 Review.